Monday, June 25, 2012
Last week's deal between Seaside
Therapeutics Inc. and Roche
has a slew of moving parts, with a different driver for each party. The key for
the biotech was granting Roche an option to its lead fragile X syndrome
program, which could allow Seaside to leverage the pharma's commercial muscle.
Meanwhile, the pharma gains freedom to operate in the mGluR5 antagonist space,
both in terms of IP and running clinical trials.
Fragile X syndrome is the most
common known genetic form of autism. It is characterized by impaired neural and
cognitive development caused by transcriptional silencing of a gene encoding
the fragile X mental retardation protein (FMRP) (see BioCentury, Nov. 2,